Verve Therapeutics Inc., a clinical-stage company specializing in genetic medicines for cardiovascular disease, has announced new equity awards under its 2024 Inducement Stock Incentive Plan. On May 30, 2025, the company granted stock options for a total of 65,000 shares and 22,000 restricted stock units (RSUs) to four new employees. The stock options have an exercise price of $4.45 per share, reflecting the closing price on the grant date, and will vest over four years, with 25% vesting after one year and the remainder vesting monthly thereafter. The RSUs will vest in equal annual installments over three years, beginning on July 1, 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.